543 related articles for article (PubMed ID: 23344728)
1. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.
Kim YG; Hahn S; Oh TJ; Kwak SH; Park KS; Cho YM
Diabetologia; 2013 Apr; 56(4):696-708. PubMed ID: 23344728
[TBL] [Abstract][Full Text] [Related]
2. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.
Kim YG; Hahn S; Oh TJ; Park KS; Cho YM
Diabetes Obes Metab; 2014 Oct; 16(10):900-9. PubMed ID: 24655583
[TBL] [Abstract][Full Text] [Related]
3. Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.
Fujita K; Kaneko M; Narukawa M
Clin Drug Investig; 2017 Mar; 37(3):219-232. PubMed ID: 27848150
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
5. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Zhang F; Xu S; Tang L; Pan X; Tong N
Front Endocrinol (Lausanne); 2020; 11():288. PubMed ID: 32582019
[No Abstract] [Full Text] [Related]
6. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis.
Cai X; Han X; Luo Y; Ji L
J Diabetes; 2015 May; 7(3):347-59. PubMed ID: 25043156
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.
Cai X; Yang W; Zhou L; Zhang S; Han X; Ji L
Endocrine; 2015 Dec; 50(3):590-7. PubMed ID: 26048437
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis.
Kim YG; Min SH; Hahn S; Oh TJ; Park KS; Cho YM
Diabetes Res Clin Pract; 2016 Jun; 116():86-95. PubMed ID: 27321321
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.
Gao W; Wang Q; Yu S
J Endocrinol Invest; 2016 Sep; 39(9):1061-74. PubMed ID: 27072669
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
14. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
Foley JE; Bhosekar V; Kawamori R
Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.
Park H; Park C; Kim Y; Rascati KL
Ann Pharmacother; 2012 Nov; 46(11):1453-69. PubMed ID: 23136353
[TBL] [Abstract][Full Text] [Related]
16. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients.
Esposito K; Chiodini P; Maiorino MI; Capuano A; Cozzolino D; Petrizzo M; Bellastella G; Giugliano D
BMJ Open; 2015 Feb; 5(2):e005892. PubMed ID: 25687897
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis.
Wang B; Sun Y; Sang Y; Liu X; Liang J
Medicine (Baltimore); 2018 Nov; 97(46):e12633. PubMed ID: 30431561
[TBL] [Abstract][Full Text] [Related]
19. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials.
Esposito K; Chiodini P; Maiorino MI; Bellastella G; Capuano A; Giugliano D
BMJ Open; 2014 Jun; 4(6):e005442. PubMed ID: 24916090
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
